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Abstract
© 2018, Pharmainfo Publications. All rights reserved. The article presents the results of research
into the role of systemic inflammation in the pathogenesis and clinical presentation of functional
dyspepsia. Elevated serum concentrations of pro-inflammatory cytokines, including TNF-α, IL-1ß,
IL-6, IL-8, and low IL-10 levels have been reported in patients with functional dyspepsia. Serum
cytokine profiles have been shown to correlate positively with the most pronounced clinical sign
of functional dyspepsia, epigastric pain. The serum levels of pro-inflammatory cytokines, TNF-α,
IL-1ß and IL-6, were significantly higher in patients with functional dyspepsia and Helicobacter
pylori infection. Elevated levels of TNF-α, IL-1ß and IL-8 have been shown to correlate with
functional dyspepsia and postprandial distress syndrome, and high concentrations of IL-1β were
indicative  of  functional  dyspepsia  and  epigastric  pain  syndrome.  The  expression  of  pro-
inflammatory cytokines in the functional dyspepsia group was much less pronounced than in
patients with peptic ulcer, however, it was significantly higher than in healthy controls. The
frequency of occurrence of hypercytokinemia in patients with functional dyspepsia has been
reported to range from 26 to 41%, from 61 to 80% in the peptic ulcer group and from 2 to 7% in
healthy controls. We conclude that cytokine imbalance plays a critical role in the pathogenesis
of functional dyspepsia.
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